Evidence map›Paper›PMID 42883739›Full record

ReviewInternational journal of molecular sciences2026

Closing the Gap: Advances and Barriers on

Julie Krier, Jontana Allkja, Alexandra Mónica Bastos Viana da Costa, Francisco A M Silva, Célia Fortuna Rodrigues

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Julie KrierDepartment of Pharmaceutical Sciences, University Institute of Health Sciences (IUCS-CESPU), 4585-116 Gandra, Portugal.
Jontana AllkjaOpen Innovation Hub for Antimicrobial Surfaces, Surface Science Research Centre, School of Physical Sciences, University of Liverpool, Liverpool L69 3BX, UK.ORCID 0000-0001-9086-4862
Alexandra Mónica Bastos Viana da CostaAssociate Laboratory i4HB-Institute for Health and Bioeconomy, University Institute of Health Sciences-CESPU, 4585-116 Gandra, Portugal.ORCID 0000-0003-2245-5316
Francisco A M SilvaDepartment of Pharmaceutical Sciences, University Institute of Health Sciences (IUCS-CESPU), 4585-116 Gandra, Portugal.ORCID 0000-0002-5960-3610
Célia Fortuna RodriguesDepartment of Pharmaceutical Sciences, University Institute of Health Sciences (IUCS-CESPU), 4585-116 Gandra, Portugal.ORCID 0000-0001-8633-2230

Funding

Fundação para a Ciência e Tecnologia UID/04378/2025
6 · The paper itself

Abstract

Invasive Candidiasis (IC) remains a critical threat to global health. Primarily caused by

Indexed as

CandidaCandidiasisCandidiasis, InvasiveFungal VaccinesVaccine DevelopmentAnimalsHumansFungal Vaccinesantifungal vaccineCandida aurisCandida spp.invasive candidiasismultidrug resistanceNDV-3Areverse vaccinologyRVVCtrained immunity

Identifiers

PMID42883739
PMCPMC13665181

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.